Our Clients' exciting journeys
Setting new medical standards
Introducing some of our most appreciated Clients, striving for commercial success with innovative and promising therapy concepts:
BioVentrix, Inc. (USA) brings to market a new and unique device therapy to restore adequate heart function in patients with Heart Failure (HF) after myocardial infarct. The CE marked ReviventTC(R) system allows for minimal invasive reconstruction of the heart's left ventricle (LV) permanently impaired by the loss of functional muscle mass. This results in immediate increase of LV performance and patients report of a significant improvement in their quality of life. Currently, the company launches REVIVE-HF, a large multicenter post-market clinical study in Europe, and works with well known heart centers and opinion leaders to bring the therapy into clinical routine.
Miracor Medical Systems GmbH (Austria) is developing and commercializing a breakthrough technology to improve outcomes for heart attack patients. InterMedCare had been selected to support the company in the clinical validation of this innovative therapy concept together with a group of leading cardiac centers. We also assisted in gaining regulatory approvals, preparing the market with opinion leader advocacy and paving the way for reimbursement in Germany.
LoneStar Heart, Inc. (USA) develops new therapies to preserve and restore adequate heart function in patients with Advanced Heart Failure (HF). Its broad portfolio of products include Algisyl™, a proprietary biopolymer to be directly injected into the heart muscle. Currently, the company will present the two-year follow-up data of the international multicenter clinical study AUGMENT-HF, continues to develop an even less invasive technology approach for therapy delivery and prepares for early commercialization in Europe.
Cardiola AG (Switzerland) has developed and commercializes the m.pulse®, the world’s only non-invasive circulatory support system for heart failure patients primarily to be used in homecare. InterMedCare assisted the company to develop and implement strategies to bring its innovative therapy approach into the hospital market and to explore its international business opportunities.